Which has better valuation & earnings, NYXH or PDEX?

Pro-Dex has higher revenue and earnings than Nyxoah. Nyxoah is trading at a lower price-to-earnings ratio than Pro-Dex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nyxoah $15.33M 3.81 -$101.92M -$2.48 N/A Pro-Dex $66.59M 2.97 $8.98M $3.62 17.12

Is NYXH or PDEX more profitable?

Pro-Dex has a net margin of 16.08% compared to Nyxoah's net margin of -543.21%. Pro-Dex's return on equity of 22.78% beat Nyxoah's return on equity. Company Net Margins Return on Equity Return on Assets Nyxoah -543.21% -163.73% -80.24% Pro-Dex 16.08% 22.78% 14.30%

Does the media refer more to NYXH or PDEX?

In the previous week, Nyxoah had 3 more articles in the media than Pro-Dex. MarketBeat recorded 6 mentions for Nyxoah and 3 mentions for Pro-Dex. Pro-Dex's average media sentiment score of 0.85 beat Nyxoah's score of 0.57 indicating that Pro-Dex is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nyxoah 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pro-Dex 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to NYXH or TLSI?

In the previous week, TriSalus Life Sciences had 2 more articles in the media than Nyxoah. MarketBeat recorded 8 mentions for TriSalus Life Sciences and 6 mentions for Nyxoah. Nyxoah's average media sentiment score of 0.57 beat TriSalus Life Sciences' score of 0.21 indicating that Nyxoah is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nyxoah 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive TriSalus Life Sciences 0 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation and earnings, NYXH or APYX?

Apyx Medical has higher revenue and earnings than Nyxoah. Apyx Medical is trading at a lower price-to-earnings ratio than Nyxoah, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nyxoah $15.33M 3.81 -$101.92M -$2.48 N/A Apyx Medical $52.84M 3.78 -$11.21M -$0.22 N/A

Is NYXH or APYX more profitable?

Apyx Medical has a net margin of -16.40% compared to Nyxoah's net margin of -543.21%. Apyx Medical's return on equity of -88.47% beat Nyxoah's return on equity. Company Net Margins Return on Equity Return on Assets Nyxoah -543.21% -163.73% -80.24% Apyx Medical -16.40% -88.47% -14.94%

Which has higher earnings and valuation, RXST or NYXH?

RxSight has higher revenue and earnings than Nyxoah. RxSight is trading at a lower price-to-earnings ratio than Nyxoah, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio RxSight $127.48M 1.51 -$38.94M -$1.13 N/A Nyxoah $15.33M 3.81 -$101.92M -$2.48 N/A

Is RXST or NYXH more profitable?

RxSight has a net margin of -36.58% compared to Nyxoah's net margin of -543.21%. RxSight's return on equity of -17.01% beat Nyxoah's return on equity. Company Net Margins Return on Equity Return on Assets RxSight -36.58% -17.01% -15.12% Nyxoah -543.21% -163.73% -80.24%

Is LUCD or NYXH more profitable?

Nyxoah has a net margin of -543.21% compared to Lucid Diagnostics' net margin of -876.72%. Lucid Diagnostics' return on equity of 0.00% beat Nyxoah's return on equity. Company Net Margins Return on Equity Return on Assets Lucid Diagnostics -876.72% N/A -116.26% Nyxoah -543.21% -163.73% -80.24%

Does the media prefer LUCD or NYXH?

In the previous week, Lucid Diagnostics had 6 more articles in the media than Nyxoah. MarketBeat recorded 12 mentions for Lucid Diagnostics and 6 mentions for Nyxoah. Nyxoah's average media sentiment score of 0.57 beat Lucid Diagnostics' score of 0.53 indicating that Nyxoah is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lucid Diagnostics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nyxoah 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Nyxoah (NYXH) Competitors

$1.50 +0.12 (+8.27%)

As of 11:06 AM Eastern

Compare

NYXH vs. PDEX, TLSI, APYX, RXST, and LUCD

Should you buy Nyxoah stock or one of its competitors? MarketBeat compares Nyxoah with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Nyxoah include Pro-Dex (PDEX), TriSalus Life Sciences (TLSI), Apyx Medical (APYX), RxSight (RXST), and Lucid Diagnostics (LUCD). These companies are all part of the "medical equipment" industry.

How does Nyxoah compare to Pro-Dex?

Nyxoah (NASDAQ:NYXH) and Pro-Dex (NASDAQ:PDEX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, media sentiment, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.

In the previous week, Nyxoah had 3 more articles in the media than Pro-Dex. MarketBeat recorded 6 mentions for Nyxoah and 3 mentions for Pro-Dex. Pro-Dex's average media sentiment score of 0.85 beat Nyxoah's score of 0.57 indicating that Pro-Dex is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nyxoah	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pro-Dex	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

15.3% of Pro-Dex shares are owned by institutional investors. 17.1% of Nyxoah shares are owned by insiders. Comparatively, 45.9% of Pro-Dex shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Nyxoah has a beta of 1.55, suggesting that its share price is 55% more volatile than the broader market. Comparatively, Pro-Dex has a beta of -0.02, suggesting that its share price is 102% less volatile than the broader market.

Pro-Dex has a net margin of 16.08% compared to Nyxoah's net margin of -543.21%. Pro-Dex's return on equity of 22.78% beat Nyxoah's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nyxoah	-543.21%	-163.73%	-80.24%
Pro-Dex	16.08%	22.78%	14.30%

Nyxoah currently has a consensus target price of $7.67, suggesting a potential upside of 409.41%. Pro-Dex has a consensus target price of $70.00, suggesting a potential upside of 12.97%. Given Nyxoah's higher possible upside, analysts plainly believe Nyxoah is more favorable than Pro-Dex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nyxoah	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Pro-Dex	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.33

Pro-Dex has higher revenue and earnings than Nyxoah. Nyxoah is trading at a lower price-to-earnings ratio than Pro-Dex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nyxoah	$15.33M	3.81	-$101.92M	-$2.48	N/A
Pro-Dex	$66.59M	2.97	$8.98M	$3.62	17.12

Summary

Pro-Dex beats Nyxoah on 11 of the 16 factors compared between the two stocks.

How does Nyxoah compare to TriSalus Life Sciences?

Nyxoah (NASDAQ:NYXH) and TriSalus Life Sciences (NASDAQ:TLSI) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, earnings, risk, analyst recommendations, valuation and dividends.

TriSalus Life Sciences has a net margin of -60.85% compared to Nyxoah's net margin of -543.21%. TriSalus Life Sciences' return on equity of 0.00% beat Nyxoah's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nyxoah	-543.21%	-163.73%	-80.24%
TriSalus Life Sciences	-60.85%	N/A	-69.91%

2.6% of TriSalus Life Sciences shares are held by institutional investors. 17.1% of Nyxoah shares are held by insiders. Comparatively, 16.3% of TriSalus Life Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

TriSalus Life Sciences has higher revenue and earnings than Nyxoah. TriSalus Life Sciences is trading at a lower price-to-earnings ratio than Nyxoah, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nyxoah	$15.33M	3.81	-$101.92M	-$2.48	N/A
TriSalus Life Sciences	$44.88M	5.76	-$39.23M	-$1.41	N/A

In the previous week, TriSalus Life Sciences had 2 more articles in the media than Nyxoah. MarketBeat recorded 8 mentions for TriSalus Life Sciences and 6 mentions for Nyxoah. Nyxoah's average media sentiment score of 0.57 beat TriSalus Life Sciences' score of 0.21 indicating that Nyxoah is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nyxoah	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
TriSalus Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Nyxoah currently has a consensus target price of $7.67, indicating a potential upside of 409.41%. TriSalus Life Sciences has a consensus target price of $7.50, indicating a potential upside of 78.23%. Given Nyxoah's higher probable upside, equities research analysts clearly believe Nyxoah is more favorable than TriSalus Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nyxoah	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
TriSalus Life Sciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Nyxoah has a beta of 1.55, meaning that its share price is 55% more volatile than the broader market. Comparatively, TriSalus Life Sciences has a beta of 0.48, meaning that its share price is 52% less volatile than the broader market.

Summary

TriSalus Life Sciences beats Nyxoah on 9 of the 14 factors compared between the two stocks.

How does Nyxoah compare to Apyx Medical?

Nyxoah (NASDAQ:NYXH) and Apyx Medical (NASDAQ:APYX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, institutional ownership, analyst recommendations and risk.

Nyxoah presently has a consensus target price of $7.67, suggesting a potential upside of 409.41%. Apyx Medical has a consensus target price of $6.50, suggesting a potential upside of 36.10%. Given Nyxoah's higher probable upside, research analysts clearly believe Nyxoah is more favorable than Apyx Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nyxoah	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Apyx Medical	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

55.3% of Apyx Medical shares are held by institutional investors. 17.1% of Nyxoah shares are held by insiders. Comparatively, 15.2% of Apyx Medical shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Nyxoah had 5 more articles in the media than Apyx Medical. MarketBeat recorded 6 mentions for Nyxoah and 1 mentions for Apyx Medical. Apyx Medical's average media sentiment score of 1.89 beat Nyxoah's score of 0.57 indicating that Apyx Medical is being referred to more favorably in the news media.

Company	Overall Sentiment
Nyxoah	Positive
Apyx Medical	Very Positive

Apyx Medical has a net margin of -16.40% compared to Nyxoah's net margin of -543.21%. Apyx Medical's return on equity of -88.47% beat Nyxoah's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nyxoah	-543.21%	-163.73%	-80.24%
Apyx Medical	-16.40%	-88.47%	-14.94%

Nyxoah has a beta of 1.55, indicating that its share price is 55% more volatile than the broader market. Comparatively, Apyx Medical has a beta of 1.39, indicating that its share price is 39% more volatile than the broader market.

Apyx Medical has higher revenue and earnings than Nyxoah. Apyx Medical is trading at a lower price-to-earnings ratio than Nyxoah, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nyxoah	$15.33M	3.81	-$101.92M	-$2.48	N/A
Apyx Medical	$52.84M	3.78	-$11.21M	-$0.22	N/A

Summary

Apyx Medical beats Nyxoah on 11 of the 17 factors compared between the two stocks.

How does Nyxoah compare to RxSight?

RxSight (NASDAQ:RXST) and Nyxoah (NASDAQ:NYXH) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, earnings, dividends, profitability, valuation and risk.

RxSight has a beta of 1.14, meaning that its stock price is 14% more volatile than the broader market. Comparatively, Nyxoah has a beta of 1.55, meaning that its stock price is 55% more volatile than the broader market.

RxSight has a net margin of -36.58% compared to Nyxoah's net margin of -543.21%. RxSight's return on equity of -17.01% beat Nyxoah's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RxSight	-36.58%	-17.01%	-15.12%
Nyxoah	-543.21%	-163.73%	-80.24%

In the previous week, Nyxoah had 5 more articles in the media than RxSight. MarketBeat recorded 6 mentions for Nyxoah and 1 mentions for RxSight. RxSight's average media sentiment score of 1.89 beat Nyxoah's score of 0.57 indicating that RxSight is being referred to more favorably in the media.

Company	Overall Sentiment
RxSight	Very Positive
Nyxoah	Positive

78.8% of RxSight shares are held by institutional investors. 10.1% of RxSight shares are held by insiders. Comparatively, 17.1% of Nyxoah shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

RxSight presently has a consensus price target of $9.44, indicating a potential upside of 103.76%. Nyxoah has a consensus price target of $7.67, indicating a potential upside of 409.41%. Given Nyxoah's stronger consensus rating and higher possible upside, analysts clearly believe Nyxoah is more favorable than RxSight.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RxSight	3 Sell rating(s)	10 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.93
Nyxoah	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

RxSight has higher revenue and earnings than Nyxoah. RxSight is trading at a lower price-to-earnings ratio than Nyxoah, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RxSight	$127.48M	1.51	-$38.94M	-$1.13	N/A
Nyxoah	$15.33M	3.81	-$101.92M	-$2.48	N/A

Summary

RxSight beats Nyxoah on 8 of the 15 factors compared between the two stocks.

How does Nyxoah compare to Lucid Diagnostics?

Lucid Diagnostics (NASDAQ:LUCD) and Nyxoah (NASDAQ:NYXH) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings, profitability and risk.

Nyxoah has a net margin of -543.21% compared to Lucid Diagnostics' net margin of -876.72%. Lucid Diagnostics' return on equity of 0.00% beat Nyxoah's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lucid Diagnostics	-876.72%	N/A	-116.26%
Nyxoah	-543.21%	-163.73%	-80.24%

Lucid Diagnostics has higher earnings, but lower revenue than Nyxoah. Lucid Diagnostics is trading at a lower price-to-earnings ratio than Nyxoah, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lucid Diagnostics	$5.13M	39.75	-$58.01M	-$0.47	N/A
Nyxoah	$15.33M	3.81	-$101.92M	-$2.48	N/A

In the previous week, Lucid Diagnostics had 6 more articles in the media than Nyxoah. MarketBeat recorded 12 mentions for Lucid Diagnostics and 6 mentions for Nyxoah. Nyxoah's average media sentiment score of 0.57 beat Lucid Diagnostics' score of 0.53 indicating that Nyxoah is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lucid Diagnostics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nyxoah	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lucid Diagnostics currently has a consensus target price of $4.19, indicating a potential upside of 316.67%. Nyxoah has a consensus target price of $7.67, indicating a potential upside of 409.41%. Given Nyxoah's higher probable upside, analysts clearly believe Nyxoah is more favorable than Lucid Diagnostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lucid Diagnostics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Nyxoah	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

74.0% of Lucid Diagnostics shares are held by institutional investors. 6.8% of Lucid Diagnostics shares are held by company insiders. Comparatively, 17.1% of Nyxoah shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Lucid Diagnostics has a beta of 1.08, indicating that its stock price is 8% more volatile than the broader market. Comparatively, Nyxoah has a beta of 1.55, indicating that its stock price is 55% more volatile than the broader market.

Summary

Lucid Diagnostics and Nyxoah tied by winning 8 of the 16 factors compared between the two stocks.

Get Nyxoah News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NYXH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NYXH vs. The Competition

Export

Metric	Nyxoah	MEDICAL INFO SYS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$58.34M	$1.55B	$6.50B	$12.32B
Dividend Yield	N/A	N/A	2.67%	5.66%
P/E Ratio	-0.61	77.74	24.00	24.65
Price / Sales	3.81	21.95	543.88	171.03
Price / Cash	N/A	22.98	27.48	37.92
Price / Book	1.05	4.94	10.73	6.84
Net Income	-$101.92M	-$54.76M	$3.56B	$337.45M
7 Day Performance	8.27%	-0.28%	1.34%	2.48%
1 Month Performance	-51.14%	1.46%	2.25%	4.36%
1 Year Performance	-80.04%	-4.26%	26.20%	32.45%

Nyxoah Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NYXH Nyxoah	3.439 of 5 stars	$1.51 +8.3%	$7.67 +409.4%	-81.6%	$58.34M	$15.33M	N/A	110	Gap Up
PDEX Pro-Dex	2.9446 of 5 stars	$65.00 flat	$70.00 +7.7%	+57.2%	$207.35M	$66.59M	17.96	140	Positive News Analyst Upgrade High Trading Volume
TLSI TriSalus Life Sciences	3.5039 of 5 stars	$3.34 +4.0%	$7.50 +124.6%	-27.4%	$205.13M	$44.88M	N/A	106	Gap Down
APYX Apyx Medical	2.617 of 5 stars	$4.86 +1.9%	$6.50 +33.7%	+168.0%	$203.49M	$52.84M	N/A	270	Positive News
RXST RxSight	3.435 of 5 stars	$4.91 -0.8%	$9.44 +92.4%	-66.9%	$203.26M	$127.48M	N/A	220	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NYXH) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nyxoah (NYXH) Competitors